All In Biotech

Drug Trial Radar · NCT00144781

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

A Multicenter, Multinational, Randomized, Dose-Optimization Study of the Safety and Pharmacodynamic Response of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I

Last checked: Nov 20, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

34

Actual

Start

Dec 2004

Primary completion

Jan 2006

Study completion Jan 2006

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
BioMarin/Genzyme LLC
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).

Conditions

  • Mucopolysaccharidosis I
  • Hurler's Syndrome
  • Hurler-Scheie Syndrome
  • Scheie Syndrome

Interventions

  • Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological

    0.58 mg/kg every week

  • Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological

    1.2 mg/kg every week

  • Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological

    1.2 mg/kg every other week

  • Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological

    1.8 mg/kg every other week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) LevelTime frame: Baseline to 26 Weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Universidade Federal de Minas Gerais

    Belo Horizonte, Brazil

  • Hospital de Clinical de Porto Alegre

    Porto Alegre, Brazil

  • Universidade Federal de Sao Paulo

    São Paulo, Brazil

  • Hospital Infantil Joana de Gusmao

    Florianópolis, Santa Catarina, Brazil

  • Division of Clinical and Metabolic Genetics

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.